UBS AM’s Beta Bionics BBNX Stock Holding History

UBS AM’s Portfolio BBNX Stock Details BBNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.38K	Hold	88	–	–	﹤0.01%	3586
2026 Q1	$882	Sell	88 -17	-16%	-$251	﹤0.01%	3691
2025 Q4	$3.2K	Buy	+105	New	+$2.8K	﹤0.01%	3062

Other funds holding BBNX

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

UBS AM's BBNX Position: Q2 2026 in Review

UBS AM held its Beta Bionics (BBNX) position steady in Q2 2026 at 88 shares worth $1.38K. The position accounts for ﹤0.01% of the portfolio, ranked #3586.

UBS AM first reported a position in BBNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.2K in Q4 2025. 134 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

UBS AM held 88 shares of Beta Bionics worth $1.38K as of Q2 2026.
UBS AM left its Beta Bionics share count unchanged in Q2 2026.
Beta Bionics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3586 holding.
UBS AM first reported a position in Beta Bionics in Q4 2025 and has held it in 3 quarters since.
UBS AM's Beta Bionics position peaked at $3.2K in Q4 2025.
134 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.